NCT07645924
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
Recruiting
PHASE3Ages 18–75InterventionalTreatmentKallyope Inc.
~1,800 participants
Updated 2026-07-30 on ClinicalTrials.gov
What's tested:ElismetrepPlacebo
At a glance
Recruiting sites
82 of 115 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Pain freedom at 2 hours post-dose
Measured over Two hours post-dose
+1 more outcome measured
Conditions
Where it's being run
115 sites across 35 statesCalifornia18
Texas10
Nevada7
New York7
Utah6
Missouri5
North Carolina5
Pennsylvania5
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Exclusion
3 months prior to screening.
What this trial measures
- Pain freedom at 2 hours post-doseTwo hours post-dose
Percentage of participants that report no pain at 2 hours post-dose. Pain will be measured on a 4-point Likert scale (0=none, 1=mild, 2=moderate, 3=severe).
- Freedom from most bothersome symptoms (MBS) at 2 hours post-doseTwo hours post-dose
Percentage of participants that report absence of their MBS (nausea, phonophobia, or photophobia) at 2 hours post-dose. MBS will be measured using a binary scale (0=absent, 1=present).